Tag: cell therapy human raw materials market research

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Cell Therapy Human Raw Materials Market Growth Potential: How Will Market Size Shift Through 2030?

The market for cell therapy human raw materials has experienced significant expansion recently. This market is projected to increase from $3.36 billion in 2025 to $4.03 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 19.8%. Historically, this expansion was driven by the early adoption of stem cell therapies, the broadening of academic research in cell therapy, a rise in clinical trials for cell-based treatments, enhanced access to human-derived biological materials, and increased funding for regenerative medicine research.

The cell therapy human raw materials market size is anticipated to undergo significant expansion in the coming years. It is projected to achieve a valuation of $7.71 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 17.6%. This growth during the forecast period can be attributed to an increase in approved cell therapy products, growing demand for allogeneic and autologous therapies, intensified regulatory oversight on raw material quality, the expansion of commercial-scale cell therapy manufacturing, and the growth of oncology-focused cell therapies. Prominent trends for the forecast period include a rising demand for xeno-free and human-derived raw materials, a greater emphasis on GMP-grade and clinical-grade inputs, increasing standardization of human cell sourcing and processing, an expansion of raw material requirements for advanced cell therapies, and the establishment of long-term supply agreements for critical human raw materials.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=58580129&type=smp&name=Cell%20Therapy%20Human%20Raw%20Materials%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Cell Therapy Human Raw Materials Market Growth Catalysts And Demand Drivers

The increasing acceptance of regenerative medicine is anticipated to propel the cell therapy human raw materials market into the future. Regenerative medicine encompasses therapeutic strategies designed to repair, replace, or renew impaired tissues and organs, employing techniques such as stem cells, gene therapy, tissue engineering, or other biological methods to restore proper function. Its adoption is expanding because of breakthroughs in biotechnology, a deeper comprehension of cellular processes, the rising need for personalized treatment, and its capability to meet currently unaddressed medical requirements. The cell therapy human raw materials market plays a crucial role in regenerative medicine by providing vital biological components necessary for the creation of standardized, efficacious, and dependable cell-based treatments. For example, data from August 2023, reported by the Alliance for Regenerative Medicine, a US-based non-profit entity, showed a global count of 2,760 cell, gene, and tissue-engineering therapeutic developers in Q1 2023, representing a 101% increase from the 1,369 developers recorded in Q1 2022. Consequently, the growing integration of regenerative medicine is propelling the cell therapy human raw materials market.

Cell Therapy Human Raw Materials Market Segment Landscape: Which Areas Lead Development?

The cell therapy human raw materials market covered in this report is segmented –

1) By Product: Cell Culture Media, Cell Culture Sera, Cell Culture Supplements, Reagents And Buffers, Other Raw Materials

2) By Type Of Cell Therapy: Dendritic Cell Therapy, Natural Killer (NK) Cell Therapy, Stem Cell Therapy, T-Cell Therapy

3) By End-Use: Biopharmaceutical And Pharmaceutical Companies, Contract Research Organizations (CROs) And Contract Manufacturing Organization (CMOs), Academic And Research Institutions

Subsegments:

1) By Cell Culture Media: Serum-Free Media, Serum-Based Media, Defined Media, Specialized Media (E.G., For Stem Cells)

2) By Cell Culture Sera: Human Serum

3) By Cell Culture Supplements: Growth Factors, Cytokines, Peptides

4) By Reagents And Buffers: Enzymes (E.G., Trypsin), Ph Buffers, Cryoprotectants

5) By Other Raw Materials: Cell-Free DNA, Plasma And Platelet-Rich Plasma (PRP)

Cell Therapy Human Raw Materials Market Trends Shaping Long-Term Demand

Leading firms within the cell therapy human raw materials market are progressively concentrating on creating chemically defined cell culture mediums to expedite the advancement of cell therapies. Such a medium serves as a nutrient-dense solution, specifically formulated to supply the crucial nutrients, growth factors, and environmental conditions required for the in vitro growth and proliferation of cells outside their natural habitat. An example of this trend occurred in May 2023 when Lonza Group AG, a healthcare manufacturing entity based in Switzerland, introduced its TheraPEAK T-VIVO Cell Culture Medium. This new product boasts a chemically defined, serum-free, and animal component-free composition, incorporates recombinant proteins, offers superior support for cell culture and expansion, and provides application aid, thereby guaranteeing uniformity, security, and adherence to regulations in the production of cell therapies. The medium signifies considerable technological progress through its lack of animal components, precise chemical definition, and advantageous regulatory properties, all of which contribute to heightened safety, quality, and regulatory conformity.

Cell Therapy Human Raw Materials Market Industry Leaders And Competitive Landscape

Major companies operating in the cell therapy human raw materials market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group Ltd., Sartorius AG, Miltenyi Biotec, Bio-Techne Corporation, STEMCELL Technologies, PromoCell GmbH, AllCells LLC, BioIVT LLC, ACROBiosystems, Sartorius CellGenix GmbH, RoosterBio Inc., Takara Bio Inc., Grifols S.A., Charles River Laboratories, WuXi AppTec, Catalent Inc., Fujifilm Cellular Dynamics Inc., Orgenesis Inc.

View The Full Cell Therapy Human Raw Materials Market Report:

https://thebusinessresearchcompany.com/report/cell-therapy-human-raw-materials-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Cell Therapy Human Raw Materials Market Geographic Landscape: Which Region Leads Industry Growth?

North America was the largest region in the cell therapy human raw materials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell therapy human raw materials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Cell Therapy Human Raw Materials Market Expansion From $4.02 Billion In 2026 To $7.71 Billion In 2030

The market for human raw materials used in cell therapy has experienced significant expansion in recent years. Its value is projected to increase from $3.36 billion in 2025 to $4.03 billion in 2026, reflecting a compound annual growth rate (CAGR) of 19.8%. This historical growth has been driven by factors such as the early uptake of stem cell treatments, the broadening of academic investigations into cell therapy, a rising number of clinical trials focused on cell-based approaches, greater accessibility to biological materials sourced from humans, and increased funding directed toward regenerative medicine research.

The cell therapy human raw materials market is anticipated to experience significant expansion over the coming years, reaching a value of $7.71 billion by 2030, with a compound annual growth rate (CAGR) of 17.6%. Key drivers behind this forecast period growth include a rising number of approved cell therapy products, growing demand for both allogeneic and autologous therapies, heightened regulatory scrutiny regarding raw material quality, the expansion of commercial-scale cell therapy manufacturing, and an increase in oncology-focused cell therapies. Prominent trends shaping the forecast period encompass a growing preference for xeno-free and human-derived raw materials, an intensified focus on GMP-grade and clinical-grade inputs, enhanced standardization in human cell sourcing and processing, broader raw material requirements for advanced cell therapies, and the establishment of long-term supply agreements for essential human raw materials.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15759&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Cell Therapy Human Raw Materials Market Growth Drivers: What Factors Are Accelerating Expansion?

The increasing embrace of regenerative medicine is anticipated to propel the cell therapy human raw materials market forward. This field involves therapeutic methods that repair, replace, or regenerate impaired tissues and organs through stem cells, gene therapy, tissue engineering, or other biological processes aimed at restoring normal function. Its growing popularity stems from biotechnological progress, a deeper comprehension of cellular functions, a heightened demand for tailored treatments, and the capacity to tackle previously unmet medical requirements. By supplying vital biological elements necessary for creating standardized, efficient, and dependable cell-based therapies, the cell therapy human raw materials market plays a key role in bolstering regenerative medicine. As an example, in August 2023, the Alliance for Regenerative Medicine—a US nonprofit—reported 2,760 developers of cell, gene, and tissue-engineering therapies worldwide in the first quarter of 2023, a 101% increase from 1,369 developers in the same period of 2022. Consequently, the growing use of regenerative medicine is fueling the expansion of the cell therapy human raw materials market.

Cell Therapy Human Raw Materials Market Segment Outlook: Which Categories Are Expanding The Fastest?

The cell therapy human raw materials market covered in this report is segmented –

1) By Product: Cell Culture Media, Cell Culture Sera, Cell Culture Supplements, Reagents And Buffers, Other Raw Materials

2) By Type Of Cell Therapy: Dendritic Cell Therapy, Natural Killer (NK) Cell Therapy, Stem Cell Therapy, T-Cell Therapy

3) By End-Use: Biopharmaceutical And Pharmaceutical Companies, Contract Research Organizations (CROs) And Contract Manufacturing Organization (CMOs), Academic And Research Institutions

Subsegments:

1) By Cell Culture Media: Serum-Free Media, Serum-Based Media, Defined Media, Specialized Media (E.G., For Stem Cells)

2) By Cell Culture Sera: Human Serum

3) By Cell Culture Supplements: Growth Factors, Cytokines, Peptides

4) By Reagents And Buffers: Enzymes (E.G., Trypsin), Ph Buffers, Cryoprotectants

5) By Other Raw Materials: Cell-Free DNA, Plasma And Platelet-Rich Plasma (PRP)

Cell Therapy Human Raw Materials Market Trends: What Is Shaping Future Industry Growth?

Major players in the cell therapy human raw materials market are placing a growing emphasis on the creation of chemically defined cell culture media to speed up the development of cell therapies. A cell culture medium is a nutrient-dense solution that supplies vital nutrients, growth factors, and the right environmental conditions to support the growth and propagation of cells outside their natural setting. As an example, in May 2023, Lonza Group AG, a healthcare manufacturing firm based in Switzerland, introduced the TheraPEAK T-VIVO Cell Culture Medium. This product offers a chemically defined formulation that is free of serum and animal components, incorporates recombinant proteins, provides enhanced support for culture and expansion, and includes application assistance, all of which help ensure consistency, safety, and adherence to regulatory standards in cell therapy production. This medium marks a notable technological leap by removing animal-derived ingredients, featuring a chemically defined composition, and offering regulatory-friendly attributes, thereby enhancing safety, quality, and regulatory compliance.

Cell Therapy Human Raw Materials Market Key Companies And Competitive Benchmarking

Major companies operating in the cell therapy human raw materials market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group Ltd., Sartorius AG, Miltenyi Biotec, Bio-Techne Corporation, STEMCELL Technologies, PromoCell GmbH, AllCells LLC, BioIVT LLC, ACROBiosystems, Sartorius CellGenix GmbH, RoosterBio Inc., Takara Bio Inc., Grifols S.A., Charles River Laboratories, WuXi AppTec, Catalent Inc., Fujifilm Cellular Dynamics Inc., Orgenesis Inc.

Access The Complete Cell Therapy Human Raw Materials Market Report:

https://www.thebusinessresearchcompany.com/report/cell-therapy-human-raw-materials-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Cell Therapy Human Raw Materials Market Geographic Distribution And Regional Opportunities

North America was the largest region in the cell therapy human raw materials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell therapy human raw materials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Expected Market Size Of The Cell Therapy Human Raw Materials Market In 2026 And How Much Will It Reach By 2030?

The market size for cell therapy human raw materials has experienced rapid expansion over recent years. It is projected to increase from $3.36 billion in 2025 to $4.03 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 19.8%. This historical growth is attributable to factors such as the early embrace of stem cell therapies, the broadening scope of academic research in cell therapy, an increase in clinical trials for cell-based treatments, greater access to human-derived biological materials, and a rise in funding allocated to regenerative medicine research.

The market size for cell therapy human raw materials is anticipated to experience substantial expansion in the coming years. This market is projected to reach $7.71 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 17.6%. Drivers for this projected growth include a significant increase in approved cell therapy products, a growing need for both allogeneic and autologous treatments, enhanced regulatory oversight concerning raw material quality, the scaling up of commercial cell therapy production, and the proliferation of oncology-specific cell therapies. Key trends anticipated during this period encompass an elevated demand for xeno-free and human-derived raw materials, a heightened focus on GMP-grade and clinical-grade components, progressing standardization in the sourcing and processing of human cells, an broadening of raw material needs for innovative cell therapies, and the establishment of long-term supply agreements for essential human raw materials.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15759&type=smp

Which Drivers Are Advancing The Cell Therapy Human Raw Materials Market Growth?

The increasing utilization of regenerative medicine is anticipated to propel the cell therapy human raw materials market in the future. Regenerative medicine encompasses therapeutic strategies aimed at mending, substituting, or regrowing compromised tissues and organs through the application of stem cells, gene therapy, tissue engineering, or various biological processes to reinstate regular functionality. The uptake of regenerative medicine is expanding, driven by progress in biotechnology, enhanced comprehension of cellular operations, a rising need for personalized treatment, and its capacity to meet previously unfulfilled medical requirements. This cell therapy human raw materials market plays a crucial role in backing regenerative medicine by providing vital biological ingredients necessary for manufacturing consistent, efficacious, and dependable cell-based treatments. As an illustration, in August 2023, data from the Alliance for Regenerative Medicine, a US-based non-profit entity, indicated that the global count of cell, gene, and tissue-engineering therapeutic developers reached 2,760 in Q1 2023, marking a 101% increase from 1,369 developers in Q1 2022. Consequently, the growing acceptance of regenerative medicine is fueling the cell therapy human raw materials market.

Which Segment-Based Categories Are Covered In The Cell Therapy Human Raw Materials Market?

The cell therapy human raw materials market covered in this report is segmented –

1) By Product: Cell Culture Media, Cell Culture Sera, Cell Culture Supplements, Reagents And Buffers, Other Raw Materials

2) By Type Of Cell Therapy: Dendritic Cell Therapy, Natural Killer (NK) Cell Therapy, Stem Cell Therapy, T-Cell Therapy

3) By End-Use: Biopharmaceutical And Pharmaceutical Companies, Contract Research Organizations (CROs) And Contract Manufacturing Organization (CMOs), Academic And Research Institutions

Subsegments:

1) By Cell Culture Media: Serum-Free Media, Serum-Based Media, Defined Media, Specialized Media (E.G., For Stem Cells)

2) By Cell Culture Sera: Human Serum

3) By Cell Culture Supplements: Growth Factors, Cytokines, Peptides

4) By Reagents And Buffers: Enzymes (E.G., Trypsin), Ph Buffers, Cryoprotectants

5) By Other Raw Materials: Cell-Free DNA, Plasma And Platelet-Rich Plasma (PRP)

Which Trends Are Guiding The Development Of The Cell Therapy Human Raw Materials Market?

Leading companies active in the cell therapy human raw materials market are increasingly prioritizing the development of chemically defined cell culture mediums to expedite advancements in cell therapy. A cell culture medium is a nutrient-dense solution crafted to deliver crucial nutrients, growth factors, and appropriate environmental conditions essential for the in vitro growth and reproduction of cells outside their natural surroundings. For instance, in May 2023, Lonza Group AG, a Switzerland-based healthcare manufacturing organization, unveiled TheraPEAK T-VIVO Cell Culture Medium. This launch highlights a chemically defined, serum-free, and animal component-free formulation, incorporating recombinant proteins, offering enhanced support for culture and expansion, and providing application guidance, which ensures consistency, safety, and regulatory conformity in cell therapy production. This medium marks substantial technological strides through the elimination of animal components, its chemically defined nature, and regulatory-favorable characteristics, collectively contributing to improved safety, quality, and compliance with regulations.

Which Key Players Are Active In The Cell Therapy Human Raw Materials Market?

Major companies operating in the cell therapy human raw materials market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group Ltd., Sartorius AG, Miltenyi Biotec, Bio-Techne Corporation, STEMCELL Technologies, PromoCell GmbH, AllCells LLC, BioIVT LLC, ACROBiosystems, Sartorius CellGenix GmbH, RoosterBio Inc., Takara Bio Inc., Grifols S.A., Charles River Laboratories, WuXi AppTec, Catalent Inc., Fujifilm Cellular Dynamics Inc., Orgenesis Inc.

Access The Complete Cell Therapy Human Raw Materials Market Report:

https://www.thebusinessresearchcompany.com/report/cell-therapy-human-raw-materials-global-market-report

Which Region Contributes The Most To The Cell Therapy Human Raw Materials Market?

North America was the largest region in the cell therapy human raw materials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell therapy human raw materials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Cell Therapy Human Raw Materials Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=15759&type=smp

Browse Through More Reports Similar to the Global Cell Therapy Human Raw Materials Market 2026, By The Business Research Company

Cell Therapy Human Raw Materials Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-therapy-human-raw-materials-global-market-report

Cell Therapy Technologies Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-therapy-technologies-global-market-report

Cells Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/cells-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Cell Therapy Human Raw Materials Market Grow Between 2026 And 2030?

The cell therapy human raw materials market size has experienced significant expansion in recent years. This market is projected to expand from $3.36 billion in 2025 to $4.03 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 19.8%. The historic growth in this sector is primarily due to the initial embrace of stem cell therapies, the broadening of academic cell therapy research, an increase in clinical trials for cell-based treatments, enhanced availability of human-derived biological materials, and escalating investment in regenerative medicine research.

The market for human raw materials utilized in cell therapy is projected to expand significantly over the coming years. This market is anticipated to reach a valuation of $7.71 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 17.6%. This anticipated expansion during the forecast period stems from several factors, including a rise in approved cell therapy products, an increasing need for both allogeneic and autologous treatments, heightened regulatory oversight concerning raw material quality, the scaling up of commercial cell therapy production, and the proliferation of cancer-focused cell therapies. Key developments expected within this period involve a greater call for xeno-free and human-derived raw materials, a stronger focus on GMP-grade and clinical-grade inputs, the increasing standardization of human cell sourcing and processing methodologies, an broadening of raw material needs for cutting-edge cell therapies, and the establishment of long-term supply agreements for essential human raw materials.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15759&type=smp

What Significant Factors Are Influencing The Cell Therapy Human Raw Materials Market Expansion?

The increasing acceptance of regenerative medicine is projected to stimulate the cell therapy human raw materials market moving forward. Regenerative medicine refers to therapeutic approaches aimed at repairing, replacing, or regenerating damaged tissues and organs through the use of stem cells, gene therapy, tissue engineering, or other biological mechanisms to restore normal function. The adoption of regenerative medicine is expanding due to advancements in biotechnology, a deeper understanding of cellular mechanisms, growing demand for personalized medicine, and its capacity to address unmet medical needs. The cell therapy human raw materials market aids regenerative medicine by providing essential biological components necessary for producing standardized, effective, and reliable cell-based therapies. For instance, in August 2023, the Alliance for Regenerative Medicine, a US-based non-profit organization, reported 2,760 cell, gene, and tissue-engineering therapeutic developers worldwide in Q1 2023, representing a 101% rise from 1,369 developers in Q1 2022. Thus, the growing adoption of regenerative medicine is driving the cell therapy human raw materials market.

Which Segment Types Are Examined In The Cell Therapy Human Raw Materials Market Segment Study?

The cell therapy human raw materials market covered in this report is segmented –

1) By Product: Cell Culture Media, Cell Culture Sera, Cell Culture Supplements, Reagents And Buffers, Other Raw Materials

2) By Type Of Cell Therapy: Dendritic Cell Therapy, Natural Killer (NK) Cell Therapy, Stem Cell Therapy, T-Cell Therapy

3) By End-Use: Biopharmaceutical And Pharmaceutical Companies, Contract Research Organizations (CROs) And Contract Manufacturing Organization (CMOs), Academic And Research Institutions

Subsegments:

1) By Cell Culture Media: Serum-Free Media, Serum-Based Media, Defined Media, Specialized Media (E.G., For Stem Cells)

2) By Cell Culture Sera: Human Serum

3) By Cell Culture Supplements: Growth Factors, Cytokines, Peptides

4) By Reagents And Buffers: Enzymes (E.G., Trypsin), Ph Buffers, Cryoprotectants

5) By Other Raw Materials: Cell-Free DNA, Plasma And Platelet-Rich Plasma (PRP)

What Trends Are Influencing The Cell Therapy Human Raw Materials Market?

Leading companies in the cell therapy human raw materials market are increasingly focusing on the development of chemically defined cell culture mediums to accelerate the progress of cell therapies. A cell culture medium is a solution rich in nutrients, crafted to deliver vital nutrients, growth factors, and the necessary environmental conditions for cells to grow and propagate in vitro, outside their natural setting. For example, in May 2023, Lonza Group AG, a healthcare manufacturing organization based in Switzerland, introduced its TheraPEAK T-VIVO Cell Culture Medium. This product features a chemically defined, serum-free, and animal component-free composition, along with recombinant proteins, enhanced support for culture and expansion, and application assistance, thus ensuring consistency, safety, and regulatory compliance in cell therapy manufacturing. This medium signifies considerable technological progress by removing animal components, offering a chemically defined formulation, and possessing regulatory-friendly qualities, all contributing to better safety, quality, and regulatory adherence.

Which Players Are Part Of The Competitive Landscape Of The Cell Therapy Human Raw Materials Market?

Major companies operating in the cell therapy human raw materials market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group Ltd., Sartorius AG, Miltenyi Biotec, Bio-Techne Corporation, STEMCELL Technologies, PromoCell GmbH, AllCells LLC, BioIVT LLC, ACROBiosystems, Sartorius CellGenix GmbH, RoosterBio Inc., Takara Bio Inc., Grifols S.A., Charles River Laboratories, WuXi AppTec, Catalent Inc., Fujifilm Cellular Dynamics Inc., Orgenesis Inc.

Get The Full Cell Therapy Human Raw Materials Market Report:

https://www.thebusinessresearchcompany.com/report/cell-therapy-human-raw-materials-global-market-report

Which Region Accounts For The Largest Portion Of The Cell Therapy Human Raw Materials Market?

North America was the largest region in the cell therapy human raw materials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell therapy human raw materials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Cell Therapy Human Raw Materials Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/cell-therapy-human-raw-materials-global-market-report

Browse Through More Reports Similar to the Global Cell Therapy Human Raw Materials Market 2026, By The Business Research Company

Cell Therapy Human Raw Materials Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-therapy-human-raw-materials-global-market-report

Cell Therapy Technologies Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-therapy-technologies-global-market-report

Cells Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/cells-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Cell Therapy Human Raw Materials Market Evolve From 2026 To 2030?

The cell therapy human raw materials market has experienced rapid expansion in recent years. This market is projected to increase from $3.36 billion in 2025 to $4.03 billion in 2026, at a compound annual growth rate (CAGR) of 19.8%. The historical growth of this market can be attributed to factors such as the initial acceptance of stem cell therapies, the broadening of academic cell therapy research, an increase in clinical trials for cell-based treatments, the rising availability of human-derived biological materials, and a surge in investment towards regenerative medicine research.

The cell therapy human raw materials market is projected to experience substantial growth over the coming years. This market is set to reach $7.71 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 17.6%. The expansion during the forecast period is driven by several factors, including a surge in approved cell therapy products, an increasing need for allogeneic and autologous therapies, enhanced regulatory oversight on raw material quality, the scaling up of commercial cell therapy manufacturing, and the development of oncology-focused cell therapies. Key developments anticipated in this period encompass a growing preference for xeno-free and human-derived raw materials, a greater focus on GMP-grade and clinical-grade inputs, the increasing standardization of human cell sourcing and processing, an expansion of raw material requirements for advanced cell therapies, and the establishment of long-term supply agreements for critical human raw materials.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15759&type=smp

What Key Drivers Are Influencing The Growth Of The Cell Therapy Human Raw Materials Market?

The cell therapy human raw materials market is projected to be propelled by the increasing adoption of regenerative medicine moving forward. Regenerative medicine encompasses therapeutic methods focused on repairing, replacing, or regenerating compromised tissues and organs through the application of stem cells, gene therapy, tissue engineering, or other biological mechanisms to reinstate normal function. The growing embrace of regenerative medicine stems from advances in biotechnology, an improved understanding of cellular processes, the rising need for personalized medicine, and its capability to address previously unmet medical requirements. The cell therapy human raw materials market supports regenerative medicine by supplying crucial biological components necessary for producing standardized, effective, and dependable cell-based therapies. For instance, in August 2023, according to the Alliance for Regenerative Medicine, a US-based non-profit organization, there were 2,760 cell, gene, and tissue-engineering therapeutic developers worldwide in Q1 2023, marking a 101% increase from 1,369 developers in Q1 2022. Thus, the escalating adoption of regenerative medicine serves as a significant driver for the cell therapy human raw materials market.

Which Segment Areas Are Covered In The Cell Therapy Human Raw Materials Market Analysis?

The cell therapy human raw materials market covered in this report is segmented –

1) By Product: Cell Culture Media, Cell Culture Sera, Cell Culture Supplements, Reagents And Buffers, Other Raw Materials

2) By Type Of Cell Therapy: Dendritic Cell Therapy, Natural Killer (NK) Cell Therapy, Stem Cell Therapy, T-Cell Therapy

3) By End-Use: Biopharmaceutical And Pharmaceutical Companies, Contract Research Organizations (CROs) And Contract Manufacturing Organization (CMOs), Academic And Research Institutions

Subsegments:

1) By Cell Culture Media: Serum-Free Media, Serum-Based Media, Defined Media, Specialized Media (E.G., For Stem Cells)

2) By Cell Culture Sera: Human Serum

3) By Cell Culture Supplements: Growth Factors, Cytokines, Peptides

4) By Reagents And Buffers: Enzymes (E.G., Trypsin), Ph Buffers, Cryoprotectants

5) By Other Raw Materials: Cell-Free DNA, Plasma And Platelet-Rich Plasma (PRP)

What Key Developments And Trends Are Impacting The Cell Therapy Human Raw Materials Market?

Major companies operating in the cell therapy human raw materials market are increasingly prioritizing the development of chemically defined cell culture mediums to accelerate cell therapy advancement. These mediums are nutrient-rich solutions designed to provide the essential nutrients, growth factors, and environmental conditions required for the in vitro growth and propagation of cells outside their natural environment. A pertinent illustration occurred in May 2023 when Lonza Group AG, a healthcare manufacturing organization based in Switzerland, launched its TheraPEAK T-VIVO Cell Culture Medium. This new medium boasts a chemically defined, serum-free, and animal component-free formulation, incorporates recombinant proteins, and provides enhanced culture and expansion support, along with application assistance, thereby guaranteeing consistency, safety, and regulatory compliance in cell therapy production. Such features mark substantial technological advancements through the elimination of animal components, its precise chemically defined formulation, and its regulatory-friendly attributes, which collectively contribute to improved safety, quality, and regulatory adherence.

Which Global Companies Are Actively Competing In The Cell Therapy Human Raw Materials Market?

Major companies operating in the cell therapy human raw materials market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group Ltd., Sartorius AG, Miltenyi Biotec, Bio-Techne Corporation, STEMCELL Technologies, PromoCell GmbH, AllCells LLC, BioIVT LLC, ACROBiosystems, Sartorius CellGenix GmbH, RoosterBio Inc., Takara Bio Inc., Grifols S.A., Charles River Laboratories, WuXi AppTec, Catalent Inc., Fujifilm Cellular Dynamics Inc., Orgenesis Inc.

Read the full cell therapy human raw materials market report here:

https://www.thebusinessresearchcompany.com/report/cell-therapy-human-raw-materials-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Cell Therapy Human Raw Materials Market?

North America was the largest region in the cell therapy human raw materials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell therapy human raw materials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cell Therapy Human Raw Materials Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15759&type=smp

Browse Through More Reports Similar to the Global Cell Therapy Human Raw Materials Market 2026, By The Business Research Company

Cell Therapy Human Raw Materials Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-therapy-human-raw-materials-global-market-report

Cell Therapy Technologies Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-therapy-technologies-global-market-report

Cells Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/cells-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the cell therapy human raw materials market from 2026–2035 with trusted insights from The Business Research Company

What market expansion outlook does the Cell Therapy Human Raw Materials Market show for the 2026–2030 period?

The market for cell therapy human raw materials has experienced rapid expansion in recent times. This market is projected to expand from $3.36 billion in 2025 to $4.03 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 19.8%. Historically, this growth can be ascribed to several factors, including the early embrace of stem cell therapies, an increase in academic cell therapy research, the rise in clinical trials for cell-based treatments, the greater availability of human-derived biological materials, and escalating investment in regenerative medicine research.

The cell therapy human raw materials market is set for significant expansion over the next few years. It is projected to achieve a market size of $7.71 billion by 2030, demonstrating a robust compound annual growth rate (CAGR) of 17.6%. This growth throughout the forecast period is largely driven by an increase in approved cell therapy products, rising demand for both allogeneic and autologous therapies, enhanced regulatory scrutiny regarding raw material quality, the scaling up of commercial cell therapy manufacturing, and the emergence of more oncology-focused cell therapies. Prominent trends for this period encompass an escalating preference for xeno-free and human-derived raw materials, a greater emphasis on GMP-grade and clinical-grade inputs, the evolving standardization of human cell sourcing and processing, expanding requirements for raw materials in advanced cell therapies, and the formation of long-term supply agreements for critical human raw materials.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15759&type=smp

What Drivers Are Shaping The Development Of The Cell Therapy Human Raw Materials Market?

The cell therapy human raw materials market is anticipated to be driven by the increasing integration of regenerative medicine moving forward. Regenerative medicine involves therapeutic approaches designed to repair, replace, or regenerate damaged tissues and organs, utilizing methods like stem cells, gene therapy, tissue engineering, or other biological mechanisms to restore normal function. Its adoption is expanding due to advances in biotechnology, a better understanding of cellular mechanisms, the escalating demand for personalized medicine, and its capacity to address unmet medical needs. This market for human raw materials in cell therapy supports regenerative medicine by providing the essential biological components needed for developing standardized, effective, and reliable cell-based therapies. For instance, in August 2023, the Alliance for Regenerative Medicine, a US-based non-profit organization, stated that there were 2,760 cell, gene, and tissue-engineering therapeutic developers globally in Q1 2023, marking a 101% increase from the 1,369 developers in Q1 2022. Thus, the growing adoption of regenerative medicine is a key driver for the cell therapy human raw materials market.

Which Segments Are Contributing To The Growth Of The Cell Therapy Human Raw Materials Market?

The cell therapy human raw materials market covered in this report is segmented –

1) By Product: Cell Culture Media, Cell Culture Sera, Cell Culture Supplements, Reagents And Buffers, Other Raw Materials

2) By Type Of Cell Therapy: Dendritic Cell Therapy, Natural Killer (NK) Cell Therapy, Stem Cell Therapy, T-Cell Therapy

3) By End-Use: Biopharmaceutical And Pharmaceutical Companies, Contract Research Organizations (CROs) And Contract Manufacturing Organization (CMOs), Academic And Research Institutions

Subsegments:

1) By Cell Culture Media: Serum-Free Media, Serum-Based Media, Defined Media, Specialized Media (E.G., For Stem Cells)

2) By Cell Culture Sera: Human Serum

3) By Cell Culture Supplements: Growth Factors, Cytokines, Peptides

4) By Reagents And Buffers: Enzymes (E.G., Trypsin), Ph Buffers, Cryoprotectants

5) By Other Raw Materials: Cell-Free DNA, Plasma And Platelet-Rich Plasma (PRP)

Which Trends Are Guiding The Evolution Of The Cell Therapy Human Raw Materials Market?

Leading companies in the cell therapy human raw materials market are increasingly concentrating on developing chemically defined cell culture mediums to accelerate the progress of cell therapies. A cell culture medium is a nutrient-rich liquid designed to deliver essential nutrients, growth factors, and environmental conditions required for the in vitro growth and propagation of cells outside their natural environment. For example, in May 2023, Lonza Group AG, a healthcare manufacturing organization based in Switzerland, unveiled its TheraPEAK T-VIVO Cell Culture Medium. This product features a chemically defined formulation, is serum-free and animal component-free, contains recombinant proteins, offers enhanced support for culture and expansion, and provides application assistance, thereby ensuring consistency, safety, and regulatory compliance in cell therapy manufacturing. This medium signifies important technological advancements by eliminating animal components, possessing a chemically defined formulation, and exhibiting regulatory-friendly attributes, ultimately improving safety, quality, and adherence to regulations.

Who Are The Prominent Global Companies Shaping The Cell Therapy Human Raw Materials Market Landscape?

Major companies operating in the cell therapy human raw materials market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group Ltd., Sartorius AG, Miltenyi Biotec, Bio-Techne Corporation, STEMCELL Technologies, PromoCell GmbH, AllCells LLC, BioIVT LLC, ACROBiosystems, Sartorius CellGenix GmbH, RoosterBio Inc., Takara Bio Inc., Grifols S.A., Charles River Laboratories, WuXi AppTec, Catalent Inc., Fujifilm Cellular Dynamics Inc., Orgenesis Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/cell-therapy-human-raw-materials-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Cell Therapy Human Raw Materials Market?

North America was the largest region in the cell therapy human raw materials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell therapy human raw materials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Cell Therapy Human Raw Materials Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15759&type=smp

Browse Through More Reports Similar to the Global Cell Therapy Human Raw Materials Market 2026, By The Business Research Company

Cell Therapy Human Raw Materials Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-therapy-human-raw-materials-global-market-report

Cell Therapy Technologies Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-therapy-technologies-global-market-report

Cells Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/cells-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the pharmaceutical continuous manufacturing market from 2025–2034 with trusted insights from The Business Research Company

What Are The Future Growth Projections For The Pharmaceutical Continuous Manufacturing Market Size?

The cell therapy human raw materials market size has experienced swift expansion in recent years. It is projected to increase from $2.82 billion in 2024 to $3.36 billion in 2025, showing a compound annual growth rate (CAGR) of 19.3%. The historical growth can be linked to the rising prevalence of chronic diseases, an expanding geriatric population, the substantial demand for regenerative medicines, governmental funding and support, and increasing healthcare expenditure.

The cell therapy human raw materials market is anticipated to experience substantial expansion over the next few years. It is projected to reach “$6.67 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 18.7%. This growth during the forecast period is primarily attributed to expanding therapeutic applications, rising patient awareness, favorable regulatory frameworks, a growing biopharmaceutical sector, and improved manufacturing processes. Key trends expected in this period include the adoption of allogeneic therapies, the integration of artificial intelligence, an increase in off-the-shelf cell therapies, the use of 3D bioprinting technology, and the development of hybrid cell therapies.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15759&type=smp

What Core Market Drivers Are Expanding The Pharmaceutical Continuous Manufacturing Industry?

The growing embrace of regenerative medicine is projected to propel the cell therapy human raw materials market in the future. Regenerative medicine focuses on utilizing the body’s inherent healing potential or applying external elements like stem cells, tissue engineering, or gene therapy to mend, substitute, or regrow damaged tissues and organs, ultimately aiming to recover normal functionality. This field is gaining prominence due to breakthroughs in biotechnology, improved comprehension of cellular processes, an increasing need for personalized medical solutions, and its capacity to address critical unmet medical needs more efficiently. Cell therapy and human raw materials support the increased uptake of regenerative medicine by supplying vital biological elements required for cell-based treatments, thereby enabling the creation of consistent and dependable therapies for diverse health issues. A significant indicator of this trend is observed in a report from August 2023 by the Alliance for Regenerative Medicine, a US-based non-profit organization, which stated that there were 2760 cell, gene, and tissue-engineering therapeutic developers globally in Q1 2023, representing a 101% increase from 1369 in Q1 2022. Consequently, the expanding adoption of regenerative medicine is a key driver for the cell therapy human raw materials market.

What Segment Insights Are Highlighted In The Pharmaceutical Continuous Manufacturing Market Report?

The cell therapy human raw materials market covered in this report is segmented –

1) By Product: Cell Culture Media, Cell Culture Sera, Cell Culture Supplements, Reagents And Buffers, Other Raw Materials

2) By Type Of Cell Therapy: Dendritic Cell Therapy, Natural Killer (NK) Cell Therapy, Stem Cell Therapy, T-Cell Therapy

3) By End-Use: Biopharmaceutical And Pharmaceutical Companies, Contract Research Organizations (CROs) And Contract Manufacturing Organization (CMOs), Academic And Research Institutions

Subsegments:

1) By Cell Culture Media: Serum-Free Media, Serum-Based Media, Defined Media, Specialized Media (E.G., For Stem Cells)

2) By Cell Culture Sera: Fetal Bovine Serum (FBS), Human Serum, Adult Bovine Serum

3) By Cell Culture Supplements: Growth Factors, Cytokines, Peptides

4) By Reagents And Buffers: Enzymes (E.G., Trypsin), Ph Buffers, Cryoprotectants

5) By Other Raw Materials: Cell-Free DNA, Plasma And Platelet-Rich Plasma (PRP), Vials And Storage Containers

Which Notable Trends Are Transforming The Pharmaceutical Continuous Manufacturing Market Outlook?

Leading firms within the cell therapy human raw materials sector are increasingly prioritizing the creation of chemically defined cell culture mediums to expedite the progress of cell therapies. Such a medium is a solution abundant in nutrients, crafted to supply vital nutrients, growth factors, and suitable environmental settings required for the in vitro cultivation and multiplication of cells beyond their native surroundings. For example, in May 2023, Lonza Group AG, a healthcare manufacturing organization based in Switzerland, introduced its TheraPEAK T-VIVO Cell Culture Medium. This new product boasts a chemically defined, serum-free, and animal component-free makeup, includes recombinant proteins, offers improved support for cell culture and expansion, and provides application aid, thereby guaranteeing uniformity, safety, and adherence to regulations in cell therapy production. The medium signifies substantial technological progress through its lack of animal components, its chemically defined nature, and its favorable regulatory attributes, all of which contribute to enhanced safety, quality, and regulatory adherence.

Which Firms Are Driving Innovation Within The Pharmaceutical Continuous Manufacturing Market?

Major companies operating in the cell therapy human raw materials market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, GE Healthcare, Corning Incorporated, Lonza Group Ltd., Grifols S.A., WuXi AppTec, Catalent Inc., Sartorius AG, Charles River Laboratories, Bio-Rad Laboratories Inc., Pall Corporation, Bio-Techne Corporation, Miltenyi Biotec, Actylis, STEMCELL Technologies, Takara Bio Inc., Vericel Corporation, ACROBiosystems, BioIVT LLC, Orgenesis Inc., PromoCell GMBH, ViaCyte Inc., AllCells LLC, Sartorius CellGenix GmbH, Fujifilm Cellular Dynamics Inc., Mesoblast Limited, RoosterBio Inc., Thermogenesis Holdings Inc.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cell-therapy-human-raw-materials-global-market-report

What Regional Trends Are Shaping Growth In The Pharmaceutical Continuous Manufacturing Market?

North America was the largest region in the cell therapy human raw materials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell therapy human raw materials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=15759&type=smp

Browse Through More Reports Similar to the Global Pharmaceutical Continuous Manufacturing Market 2025, By The Business Research Company

Single Cell Analysis Market 2025

https://www.thebusinessresearchcompany.com/report/single-cell-analysis-market

Cell Regeneration Medicine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cell-regeneration-medicine-global-market-report

Basal Cell Carcinoma Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/basal-cell-carcinoma-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Are The Future Growth Projections For The Cell Therapy Human Raw Materials Market Size?

The market size for human raw materials for cell therapy has seen considerable expansion in the recent past. The market is projected to rise from $2.82 billion in 2024 to $3.36 billion in 2025, registering a compound annual growth rate (CAGR) of 19.3%. Factors contributing to this growth during the historical period include an increase in chronic disease cases, an aging population, a heightened need for regenerative treatments, supportive government funding, and an escalation in healthcare spending.

The market size for human raw materials in cell therapy is projected to experience a swift expansion in the forthcoming years, increasing to “$6.67 billion by 2029”, with a compound annual growth rate (CAGR) of 18.7%. This surge during the forecast period can be credited to factors such as broader therapeutic usage, increased awareness among patients, supportive regulatory policies, the expansion of the biopharmaceutical sector, and enhancements in manufacturing methods. Key trends projected in this period include the acceptance of allogeneic therapies, inclusion of artificial intelligence, growth in off-the-shelf cell therapies, implementation of 3D bioprinting technology, and progress in hybrid cell therapies.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15759&type=smp

What Market Forces Are Contributing To The Growth Of The Cell Therapy Human Raw Materials Market?

Cell therapy human raw materials market growth is expected to be fueled by the increasing adoption of regenerative medicine. This field of medicine leverages the body’s natural regenerative capabilities or employs external factors like stem cells, tissue engineering, or gene therapy to repair or regenerate damaged body tissues and organs, with a goal to restore their normal functioning. The growth of regenerative medicine has been spurred by developments in biotechnology, heightened understanding of cellular mechanisms, increasing demand for personalized medical care, and its potential to cater to unmet medical requirements more effectively. Cell therapy, along with human raw materials, enhances the adoption of regenerative medicine by supplying critical biological aspects required for cell-centred treatments. This allows the creation of uniform and dependable treatment techniques for a range of diseases. A report by the Alliance for Regenerative Medicine, a not-for-profit organization based in the US, stated that by August 2023 there were 2760 developers globally of cell, gene, and tissue-engineering therapeutics in the first quarter of 2023, an increase of 101% compared to 1369 in the same quarter of 2022. Consequently, the growing adoption of regenerative medicine propels the expansion of the cell therapy human raw materials market.

How Is The Cell Therapy Human Raw Materials Market Segmented Across Key Categories?

The cell therapy human raw materials market covered in this report is segmented –

1) By Product: Cell Culture Media, Cell Culture Sera, Cell Culture Supplements, Reagents And Buffers, Other Raw Materials

2) By Type Of Cell Therapy: Dendritic Cell Therapy, Natural Killer (NK) Cell Therapy, Stem Cell Therapy, T-Cell Therapy

3) By End-Use: Biopharmaceutical And Pharmaceutical Companies, Contract Research Organizations (CROs) And Contract Manufacturing Organization (CMOs), Academic And Research Institutions

Subsegments:

1) By Cell Culture Media: Serum-Free Media, Serum-Based Media, Defined Media, Specialized Media (E.G., For Stem Cells)

2) By Cell Culture Sera: Fetal Bovine Serum (FBS), Human Serum, Adult Bovine Serum

3) By Cell Culture Supplements: Growth Factors, Cytokines, Peptides

4) By Reagents And Buffers: Enzymes (E.G., Trypsin), Ph Buffers, Cryoprotectants

5) By Other Raw Materials: Cell-Free DNA, Plasma And Platelet-Rich Plasma (PRP), Vials And Storage Containers

What Key Trends Are Driving Growth In The Cell Therapy Human Raw Materials Market?

Significant players in the cell therapy human raw materials market are increasingly centering their efforts on the creation of chemically defined cell culture mediums in order to expedite the development of cell therapy. A cell culture medium, nourishing solution rich in essential nutrients, growth factors, and environmental conditions, is crucial for in vitro growth and propagation of cells outside their natural surroundings. For instance, in May 2023, the Switzerland-based healthcare manufacturing company Lonza Group AG introduced the TheraPEAK T-VIVO Cell Culture Medium. This product release features a chemically defined formulation that is devoid of serum or animal component, recombinant proteins, and offers enhanced culture and expansion support, as well as application help, ensuring consistency, safety, and regulatory compliance in cell therapy manufacturing. This medium is a huge leap forward technologically, with its elimination of animal ingredients, chemically defined formulation, and features favorable to regulation, thereby enhancing safety, quality, and regulatory compliance.

Which Firms Are Driving Innovation Within The Cell Therapy Human Raw Materials Market?

Major companies operating in the cell therapy human raw materials market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, GE Healthcare, Corning Incorporated, Lonza Group Ltd., Grifols S.A., WuXi AppTec, Catalent Inc., Sartorius AG, Charles River Laboratories, Bio-Rad Laboratories Inc., Pall Corporation, Bio-Techne Corporation, Miltenyi Biotec, Actylis, STEMCELL Technologies, Takara Bio Inc., Vericel Corporation, ACROBiosystems, BioIVT LLC, Orgenesis Inc., PromoCell GMBH, ViaCyte Inc., AllCells LLC, Sartorius CellGenix GmbH, Fujifilm Cellular Dynamics Inc., Mesoblast Limited, RoosterBio Inc., Thermogenesis Holdings Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/cell-therapy-human-raw-materials-global-market-report

How Do Regional Dynamics Influence The Cell Therapy Human Raw Materials Market Performance?

North America was the largest region in the cell therapy human raw materials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell therapy human raw materials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=15759&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Industry Valuation for the Pharmaceutical Continuous Manufacturing Sector?

The market size for human raw materials in cell therapy has been expanding rapidly over the last few years. It is expected to expand from $2.82 billion in 2024 to $3.36 billion in 2025, showcasing a compound annual growth rate (CAGR) of 19.3%. This significant growth during the historic period can be credited to numerous factors, including the rising occurrence of chronic diseases, the increase in the elderly population, heightened demand for regenerative treatments, substantial governmental backing and funding, and the expansion of healthcare expenditure.

There is anticipation for the cell therapy human raw materials market to grow quickly over the forthcoming years. Predictions are for it to expand to “$6.67 billion in 2029 with a compound annual growth rate (CAGR) of 18.7%.” The expected growth during the projected period could be due to factors such as broader therapeutic uses, increased patient cognizance, advantageous regulatory structures, a flourishing biopharmaceutical industry, and superior manufacturing methods. The forecast period also signals major shifts towards the adoption of allogenic therapies, artificial intelligence integration, growth in off-the-shelf cell therapies, implementation of 3D bioprinting technology, and the emergence of hybrid cell therapies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15759&type=smp

What Forces Are Driving The Growth Of The Pharmaceutical Continuous Manufacturing Market?

The proliferation of various long-term diseases is projected to boost the advancement of the pharmaceutical continuous manufacturing market in the future. These chronic diseases, typically defined as conditions lasting for at least a year, requiring ongoing medical care and affecting daily activities, serve as a primary driver. Continuous manufacturing methods aid pharmaceutical firms in optimizing the production of medications, leading to improved efficiency and reduced expenses. Access to essential medicines is also broadened, crucial for managing chronic ailments necessitating long-term medication. For example, an April 2022 report from the National Association of Chronic Disease Directors (NACDD), a non-profit Public Health organization in the US committed to chronic disease initiatives, stated that nearly 60% of American adults have a minimum of one chronic disease. Around 40% of American adults have multiple chronic conditions (MCC), which are anticipated to cost the US economy $2 trillion every year, or $8,600 per person by 2030. As a result, the escalating occurrence of numerous chronic diseases will fuel the growth of the pharmaceutical continuous manufacturing market.

The cell therapy human raw materials market covered in this report is segmented –

1) By Product: Cell Culture Media, Cell Culture Sera, Cell Culture Supplements, Reagents And Buffers, Other Raw Materials

2) By Type Of Cell Therapy: Dendritic Cell Therapy, Natural Killer (NK) Cell Therapy, Stem Cell Therapy, T-Cell Therapy

3) By End-Use: Biopharmaceutical And Pharmaceutical Companies, Contract Research Organizations (CROs) And Contract Manufacturing Organization (CMOs), Academic And Research Institutions

Subsegments:

1) By Cell Culture Media: Serum-Free Media, Serum-Based Media, Defined Media, Specialized Media (E.G., For Stem Cells)

2) By Cell Culture Sera: Fetal Bovine Serum (FBS), Human Serum, Adult Bovine Serum

3) By Cell Culture Supplements: Growth Factors, Cytokines, Peptides

4) By Reagents And Buffers: Enzymes (E.G., Trypsin), Ph Buffers, Cryoprotectants

5) By Other Raw Materials: Cell-Free DNA, Plasma And Platelet-Rich Plasma (PRP), Vials And Storage Containers

What Trends Are Currently Influencing Growth In The Pharmaceutical Continuous Manufacturing Market?

Forefront companies in the cell therapy human raw materials market are increasingly prioritizing the creation of chemically defined cell culture mediums to expedite cell therapy development. A cell culture medium is a nourishment-laden solution devised to offer vital nutrients, growth stimulants, and essential environmental conditions for the in vitro growth and propagation of cells outside their original habitat. For instance, in May 2023, a healthcare manufacturing firm based in Switzerland known as Lonza Group AG, unveiled its TheraPEAK T-VIVO Cell Culture Medium. This novel introduction includes a chemically defined formulation, devoid of serum and animal components, recombinant proteins, elevated culture support, and expansion assistance as well as application aid to ensure continual consistency, safety, and adherence to regulatory standards in cell therapy manufacturing. The significant technological progress this medium represents is marked by the elimination of animal components, chemically defined formulation, and its ability to remain regulatory-friendly. These contribute to an enhanced level of safety, quality, and regulatory compliance.

Which Companies Currently Dominate The Competitive Landscape In The Pharmaceutical Continuous Manufacturing Industry?

Major companies operating in the cell therapy human raw materials market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, GE Healthcare, Corning Incorporated, Lonza Group Ltd., Grifols S.A., WuXi AppTec, Catalent Inc., Sartorius AG, Charles River Laboratories, Bio-Rad Laboratories Inc., Pall Corporation, Bio-Techne Corporation, Miltenyi Biotec, Actylis, STEMCELL Technologies, Takara Bio Inc., Vericel Corporation, ACROBiosystems, BioIVT LLC, Orgenesis Inc., PromoCell GMBH, ViaCyte Inc., AllCells LLC, Sartorius CellGenix GmbH, Fujifilm Cellular Dynamics Inc., Mesoblast Limited, RoosterBio Inc., Thermogenesis Holdings Inc.

https://www.thebusinessresearchcompany.com/report/cell-therapy-human-raw-materials-global-market-report

Which Geographic Regions Are Driving Demand In The Pharmaceutical Continuous Manufacturing Market?

North America was the largest region in the cell therapy human raw materials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell therapy human raw materials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=15759&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model